Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

Sponsor
Universitaire Ziekenhuizen KU Leuven
Study ID
NCT05654298
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Sumatriptan — DRUG
    Sumatriptan 100 mg
  • Ubrogepant — DRUG
    Ubrogepant 100 mg

Study Details

The involvement of calcitonin gene-related peptide (CGRP) in the cinnamaldehyde-induced dermal blood flow increase and in the mechanism of action of triptans will be investigated. The capsaicin-induced dermal blood flow will be incorporated as a positive control; histamine skin pricks as a negative control. Changes in dermal blood flow will be measured with laser speckle contrast imaging.

Key Dates

Start date
Mar 15, 2022
Status verified
Mar 2022
Primary completion
Mar 15, 2023
Completion
Mar 15, 2023

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Ubrogepant
  • Experimental: Sumatriptan

Primary Outcome Measure

Change in Dermal Blood Flow induced by topical application of cinnamaldehyde [ Time Frame: AUC(0-60minutes) ]

Related Studies